stockmarketproxy
/
KYMRNasdaq SEC EDGAR

Kymera Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)·WATERTOWN, MA·FY end 12/31·CIK 1815442
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$39.2M$47.1M$78.6M$46.8M$72.8M
Gross Profit——————
Operating Income-$349.4M-$261.6M-$165.5M-$161.3M-$100.5M
Net Income-$311.4M-$223.9M-$147.0M-$154.8M-$100.2M
Operating CF-$232.9M-$194.5M-$102.8M-$153.1M-$128.9M
Capex$1.4M$12.8M$34.5M$2.8M$1.6M
Free Cash Flow-$234.3M-$207.3M-$137.3M-$155.9M-$130.5M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin-891.1%-555.8%-210.6%-344.4%-138.0%
Net Margin-794.0%-475.6%-187.0%-330.6%-137.6%
FCF Margin-597.6%-440.5%-174.7%-333.0%-179.2%
R&D / Revenue807.3%510.4%240.6%350.8%188.1%
Effective Tax0.0%—————
Debt / Equity——————
Buybacks / FCF——————

Peer comparison

Biological Products, (No Diagnostic Substances) · 5 peers
CEO Pay Ratio
KYMR
21:1
EXEL
81:1
GILD
119:1
BIIB
113:1
PCVX
48:1
IBRX
69:1
CEO total comp
KYMR
—
EXEL
$33M
GILD
$28M
BIIB
$24M
PCVX
$14M
IBRX
$13M
Net Margin
KYMR
-794.0%
EXEL
33.7%
GILD
28.9%
BIIB
13.1%
PCVX
—
IBRX
-310.2%